Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL5085250 | 0.81 | MMP8 (0.36) | TDP1MMP8CYP2C19ALDH1A1 | |
| Acetone SCHEMBL9097300 | 0.81 | ALDH1A1 (0.41) | TDP1MMP8CYP2C19ALDH1A1 | |
| Butanone SCHEMBL10818296 | 0.81 | ALDH1A1 (0.46) | TDP1MMP8CYP2C19ALDH1A1FFAR3 | |
| Acetic Acid SCHEMBL28048717 | 0.79 | ALDH1A1 (0.39) | TDP1MMP8CYP2C19ALDH1A1FFAR3 | |
| Alcohol SCHEMBL8816286 | 0.78 | TSHR (0.39) | TDP1MMP8ALDH1A1 | |
| Methyl Alcohol SCHEMBL375169 | 0.78 | TSHR (0.35) | MMP8 | |
| Hydrogen Peroxide SCHEMBL28073128 | 0.78 | TSHR (0.35) | MMP8 | |
| SCHEMBL2713018 | 0.78 | — | — | |
| SCHEMBL23992 | 0.78 | — | — | |
| SCHEMBL30487170 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380898-B1 | Process to make glucocorticoid compounds | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-1644398-B1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-2380898-A1 | Process to make glucocortisoid compounds | GLAXO GROUP LIMITED (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-1644397-B1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-7638508-B2 | Glucocorticosteroid compound having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7524970-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-04-28 | — | — | US | disclosed |
| US-20080070880-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI-INFLAMMATORY ACTIVITY | BIGGADIKE KEITH | 2008-03-20 | — | — | US | disclosed |
| US-20080015360-A1 | Novel compounds | JOHN MATTHEW P | 2008-01-17 | — | — | US | disclosed |
| US-7291609-B2 | Specific glucocorticosteroid compound having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-11-06 | — | — | US | disclosed |
| US-7288536-B2 | Specific glucocorticosteroid compound having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | disclosed |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| EP-1644397-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644398-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005005452-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| EP-1472271-A1 | PROCESS FOR THE PRODUCTION OF 6.ALPHA.,9.ALPHA-DIFLUORO-17.ALPHA.-(1-OXOPROPOXY)-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17.BETA.-CARBOTHIOIC ACID | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066654-A1 | PROCESS FOR THE PRODUCTION OF 6.ALPHA.,9.ALPHA-DIFLUORO-17.ALPHA.-(1-OXOPROPOXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17.BETA.-CARBOTHIOIC ACID | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070880-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI-INFLAMMATORY ACTIVITY | NR3C1, NR3C2, MC2R | TDP1 4761/4885MMP8 124/4885CYP2C19 422/4885 |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | NR3C1, NR3C2, MC2R | TDP1 3988/4885MMP8 108/4885CYP2C19 2198/4885 |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | NR3C2, NR3C1, NR5A1 | TDP1 4260/4885MMP8 105/4885CYP2C19 179/4885 |
| US-20080015360-A1 | Novel compounds | CYP8B1, PRMT8, CBR3 | TDP1 4470/4885MMP8 339/4885CYP2C19 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.